Navigation Links
Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent

Phase II Investigational Trial Published in CANCER: the Journal of the

American Cancer Society

SEATTLE, Jan. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) announced today that results of a phase II clinical study, published in the journal CANCER demonstrate that the addition of radioimmunotherapy (RIT) to chemotherapy for previously untreated patients with non-follicular indolent non-Hodgkin's lymphoma (NHL) was both well tolerated and effective, producing a 100 percent complete remission at end of treatment with an estimated 89 percent of patients remaining in remission at three years.

The study, conducted at the Institute of Hematology and Medical Oncology at University of Bologna, Italy, investigated the use of a single dose of Zevalin(R) (Ibritumomab Tiuxetan) as consolidation therapy following treatment with a regimen of fludarabine and mitoxantrone (FM chemotherapy) among 26 patients with newly diagnosed non-follicular indolent NHL. Non-follicular lymphomas are also referred to as intermediate grade compared to the low grade follicular or high grade diffuse B cell variety. FM chemotherapy resulted in 50 percent of patients achieving a complete remission (CR) and 30 percent achieving a partial remission (PR). Of the 20 patients (13 with CR and 7 with PR) who were evaluable for Zevalin consolidation, 100 percent obtained a CR at the end of treatment. With a median follow up of 20 months, the estimated three-year progression free survival (PFS) was 89.5 percent. The most common greater than or equal to grade 3 toxicities included neutropenia (11 patients) and thrombocytopenia (16 patients).

"This single arm, non-randomized phase II trial provides additional insights into the potential utility of RIT in intermediate grade NHL, a subtype where CRs are infrequent with rituximab therapy," noted Jack W. Singer, M.D., Chief Medical Officer of CTI.

The study results are reported in the current issue of CANCER at

Study Details

Between February 2005 and June 2006 26 eligible patients with previously untreated, indolent, nonfollicular NHL (10 marginal zone, 8 lymphocytoplasmic, and 8 small lymphocytic) were treated using a novel regimen that consisted of 6 cycles of fludarabine/mitoxantrone (FM) chemotherapy followed 6 to 10 weeks later by yttrium-90(90Y) ibritumomab tiuxetan (Zevalin(R)). After chemotherapy the overall response rate was 80.5% and included 50% CR and 30.5% PR. Of the 20 patients (13CR/7PR) who were evaluable (at least a PR with normal platelet counts and bone marrow infiltration <25%) for subsequent Zevalin, 100% obtained a CR at the end of treatment. With a median follow up of 20 months, the estimated three-year progression free survival (PFS) was 89.5 percent. The FM treatment was well-tolerated; there were no treatment-related deaths. Reversible hematologic toxicities included neutropenia grade 4 in 5 patients and grade 3 in 13 patients. Only 1 patient developed febrile neutropenia. Following Zevalin administration grade 3-4 thrombocytopenia occurred in 16 of 20 patients with grade 3-4 neutropenia reported in 11 of 20 patients. Four patients received GCSF and 3 patients received platelet transfusions. Only 1 patient experience febrile neutropenia. The authors concluded "In this study we established the feasibility, tolerability and efficacy of sequential treatement with 6 cycles of FM chemotherapy followed by 90Y ibritumomab tiuxetan as front line therapy for patients with untreated, indolent, nonfollicular NHL. To our knowledge the data represent the first demonstration in the literature of the real role of 90Y ibritumomab tiuxetan in the treatment of indolent nonfollicular NHL. Because this novel sequential treatment appears to be promising compared with results reported for CHOP and CVP- containing regimens plus rituximab, we believe the current phase II trial represents an important first step and positive new angle in therapy to combat indolent, nonfollicular NHL"

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated for the treatment of patients with relapsed or refractory low-grade or follicular B-cell NHL, including patients with Rituximab-refractory NHL. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be used by health care professionals qualified by training and experience in the safe use of radionuclides.

Patients and healthcare professionals can visit for more information.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of Zevalininclude risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with Zevalin in particular including, without limitation, the potential failure of Zevalin to prove safe and effective as consolidation therapy following treatment with a regimen of fludarabine and mitoxantrone for treatment of non-Hodgkin's lymphoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling Zevalin, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434


Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434


SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
2. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
3. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
4. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
5. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
6. SGX Initiates Phase I Trials for SGX523
7. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
8. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
9. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
(Date:10/9/2015)... REDWOOD CITY, Calif. , Oct. 9, 2015 ... a presentation will be made at the annual European Society ... th to October 14 th , 2015 at the ...  The annual EuSEM is the largest meeting of emergency medicine ... and 90 countries represented. Data from the previously ...
(Date:10/9/2015)... Oct. 9, 2015 Ansun BioPharma announced a ... of America ) regarding the compassionate use of DAS181 ... a respirator who was co-infected with influenza and parainfluenza ... of therapy, O 2 requirement was reduced and ... able to go off the respirator on day 5. ...
(Date:10/9/2015)... , Schweiz, October 9, 2015 Der ... Dr.   Yutaka Kondo und Dr.   Junko Takita ...   2015 " geht an Dr.   Yutaka ... Der " JCA-Mauvernay Award   2015 ... Dr.   Junko Takita    ™ , das ...
Breaking Medicine Technology:
... Nov. 9, 2011 BioSpecifics Technologies Corp. (NASDAQ: ... class collagenase-based products marketed as XIAFLEX® in the U.S. ... Tom Wegman, will present at the upcoming Lazard Capital ... Wednesday, November 16, 2011 in New York, NY.   ...
... 9, 2011 NeuroDerm , Ltd. ... and pharmacokinetic trial of ND0611, administered as an adjunct ... or Stalevo ® , in patients with advanced Parkinson,s ... sub-cutaneously via a dermal patch to increase the bioavailability ...
Cached Medicine Technology:
(Date:10/9/2015)... Orleans, LA (PRWEB) , ... October 09, 2015 ... ... with offices serving New Orleans and the surrounding communities, is initiating a combined ... and medical care for unwanted animals in southern Louisiana. , Animal Rescue ...
(Date:10/9/2015)... ... October 09, 2015 , ... Prescription Hope, the ... walks of life to save money on the high cost of their prescription ... per medication, individuals and families can receive their medications delivered direct from over ...
(Date:10/9/2015)... Salt Lake City, UT (PRWEB) , ... October 09, 2015 , ... ... 12-17, observes Mental Illness Awareness Week. For many teenagers facing mental illness, the stigma ... the help they need. , ViewPoint Center understands the importance of supporting teens ...
(Date:10/9/2015)... ... 09, 2015 , ... Ryan Fox, the founder and CEO ... Colorado, says the latest figures on the state’s sales of legalized marijuana acknowledge ... industry. , Last month, according to the website , Colorado's ...
(Date:10/9/2015)... ... October 09, 2015 , ... Amada Senior ... opened its newest office in Maryland – its Bethesda location. Amada ... as a project management technology consultant to many of the largest construction firms ...
Breaking Medicine News(10 mins):
... Salamon HealthDay Reporter , WEDNESDAY, Feb. 2 ... process to create ready-made, easily stored blood vessels that ... or kidney dialysis. Using donor tissue cultured on ... five years engineering the "off-the-shelf" blood vessels, which cannot ...
... , WEDNESDAY, Feb. 2 (HealthDay News) -- The huge winter ... some sections of the United States could also cause a ... while shoveling or playing in the snow, the American Academy ... of bending and heavy lifting, particularly in wet, heavy snow. ...
... doses of an inexpensive, FDA-approved hypertension medication may ... treatment. In a report in the early ... of Sciences , Massachusetts General Hospital (MGH) investigators ... by modifying the network of collagen fibers that ...
... Serious Adverse Events Consortium (iSAEC) announced today a ... to enroll subjects in research to identify genetic ... a range of serious drug-related adverse events (SAEs). ... developing SAE research cohorts, an essential component of ...
... to be more effective, Funding will support future clinical trials ... A new study led by researchers at Rhode Island ... and EpiVax. Inc, a privately owned vaccine development company in ... colonization of Helicobacter pylori ( H. pylori ) ...
... treatment, the health care services can, on the one hand, ... the other hand, find appropriate ways to care for those ... The cancer care services in Lund, Sweden, set up ... early as 1987. Twenty years later, in 2007, Lund organised ...
Cached Medicine News:
... has the highest g-force ever. But optimal ... force. Optima MAX combines maximum force, capacity, ... performance that's worlds apart from any other ... and enhanced efficiency, Optima takes productivity to ...
... of generating 694,000 x g ... rpm, Beckman Coulter's Optima L-90K ... more separations in less time. ... with a broad range of ...
... The Dimension Xpand integrated chemistry ... compact footprint to the smaller laboratory. ... the Dimension Xpand integrated chemistry system ... for the low-volume testing environment, in ...
... Dade Behring's Dimension clinical chemistry integrated systems ... Flex reagent cartridge, the power of the ... innovation of the heterogeneous module to meet ... innovation and broad test menus, the systems ...
Medicine Products: